Implications of CYP1B1 in the treatment and prognosis of breast cancer

Background Cytochrome P450 1B1 (CYP1B1) enzyme plays an important metabolic role, especially in the metabolism of xenobiotics, endogenous substances, and procarcinogens. It may be involved in tumor initiation and progression. High levels of CYP1B1 have been identified in aggressive breast cancer cel...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Beni-Suef University Journal of Basic and Applied Sciences Jg. 14; H. 1; S. 22 - 13
Hauptverfasser: Stipp, Maria Carolina, Nardin, Jeanine Marie, Casali-da-Rocha, José Claudio, Ioshii, Sérgio, Acco, Alexandra
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2025
Springer
Springer Nature B.V
SpringerOpen
Schlagworte:
Adjuvants
Analysis
Biomarkers
Breast cancer
Cancer
Cancer patients
Cancer therapies
Chemotherapy
Cytochrome P450
Cytochrome P450 system
Cytochromes P450
Development and progression
Enzymes
Estrogen receptors
Estrogens
Gene expression
Hydrocarbons
Immunohistochemistry
Kinases
Malignancy
Medical prognosis
Medicine
Medicine & Public Health
mRNA
Mutation
Oncology, Experimental
p53 Protein
Patients
Physiological aspects
Progesterone
Prognosis
Protein expression
Proteins
Receptors
RNA
Statistical analysis
Toxicity
Triple-negative breast cancer
Tumor progression
Tumor proteins
Tumors
Xenobiotics
Brazil
Puerto Rico
Washington, D.C
Immunohistochemistry
Chemotherapy
Malignancy
Cytochrome P450 system
Tumor progression
Triple-negative breast cancer
ISSN:2314-8543, 2314-8535, 2314-8543
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Cytochrome P450 1B1 (CYP1B1) enzyme plays an important metabolic role, especially in the metabolism of xenobiotics, endogenous substances, and procarcinogens. It may be involved in tumor initiation and progression. High levels of CYP1B1 have been identified in aggressive breast cancer cell lineages. The aim of the present study was to identify the expression and role of this enzyme in progression, prognosis, and clinical features of breast cancer patients. Methods Microarray paraffin-embedded tumor samples from 166 women with breast cancer were analyzed by immunohistochemical for CYP1B1. Statistical analyses were performed to correlate CYP1B1 expression with various clinical parameters among breast cancer patients. Bioinformatic tools were used to determine differential CYP1B1 mRNA and protein expression from patients in databases compared with our cohort. Results The CYP1B1 enzyme was overexpressed in 75% of breast cancer tissues. This result remained consistent regardless of the treatment regimen. Furthermore, although it was not negatively associated with overall survival, its expression was notably higher in patients who died and in patients with ER- (estrogen receptor negative) and PR- (progesterone receptor negative) tumors and p53 (protein 53) mutation carriers. These findings align with the consulted databases, which indicated a relationship between CYP1B1 expression, tumor progression, and malignancy, suggesting its potential role as a biomarker for tumor aggressiveness. Conclusions In conclusion, CYP1B1 showed a positive correlation with breast cancer malignancy, tumor progression, and toxicity effects in breast cancer patients. These findings emphasize the importance of CYP1B1 as a potential treatment target and its significance in the clinical management of breast cancer. Highlights CYP1B1 was overexpressed in 75% of breast tumor samples in a cohort of 166 women with breast cancer. Higher levels of CYP1B1 were found in patients with ER- and PR- tumors and patients with p53 mutations. CYP1B1 may be a breast cancer biomarker and linked to more aggressive forms of breast tumors. CYP1B1 may be targeted for new breast cancer treatments, especially in patients with hormone receptor-negative and p53-mutated tumor tissues.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:2314-8543
2314-8535
2314-8543
DOI:10.1186/s43088-025-00609-x